Faes Farma SA (FAE) – Company Profile and SWOT Analysis

Faes Farma SA (FAE) – Company Profile & SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

Faes Farma SA (Faes Farma) develops, manufactures, and commercializes pharmaceutical products and raw materials. The company offers prescription drugs, generic drugs, food supplements, over the counter (OTC) medications, baby foods, skin-care treatment products. It exports raw materials and finished pharmaceutical products to pharmaceutical companies worldwide. Faes Farma also owns animal nutrition and healthcare company such as Ingaso farm. The company operates manufacturing and R&D center in Leioa, Spain, laboratory, production plants, subsidiaries, and commercial offices in international markets. The company markets the products in Latin America, Asia, Europe, Africa, and the Middle East. Faes Farma is headquartered in Leioa, Spain.

Scope

• Detailed information on Faes Farma SA required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Faes Farma SA in the form of a SWOT analysis

• An in-depth view of the business model of Faes Farma SA including a breakdown and examination of key business segments

• News about Faes Farma SA, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Faes Farma SA and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Faes Farma SA as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Faes Farma SAs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Vifor Pharma Management Ltd

Laboratorios Richmond SACIF

Grifols SA

Almirall SA

Laboratorios Farmaceuticos Rovi SA

Corporacion Dermoestetica SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Faes Farma SA - Key Facts

Faes Farma SA - Key Employees

Faes Farma SA - Major Products and Services

Faes Farma SA - History

Faes Farma SA - Company Statement

Faes Farma SA - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Faes Farma SA - Business Description

Business Segment: Animal Nutrition and Health

Overview

Performance

Business Segment: Pharmaceutical and Healthcare Specialties

Overview

Performance

Business Segment: Pharmaceutical Raw Materials

Overview

Performance

R&D Overview

Faes Farma SA - Corporate Strategy

Faes Farma SA - SWOT Analysis

SWOT Analysis - Overview

Faes Farma SA - Strengths

Faes Farma SA - Weaknesses

Faes Farma SA - Opportunities

Faes Farma SA - Threats

Faes Farma SA - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Faes Farma SA, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024

Faes Farma SA, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024

Faes Farma SA, Recent Deals Summary

Section 5 – Company’s Recent Developments

May 02, 2024: Faes Farma Proposes to Appoint Eduardo Recoder de la Cuadra as its New CEO

Apr 26, 2024: Faes Farma Increases its Net Profit by 10% in the First Quarter, up to

30.4 Million Euros

Feb 20, 2024: Faes Farma Reaches a Record Net Profit of 92 Million Euros, 2.5% More Than in 2022

Feb 20, 2024: We Present Our New Website. A Renewed Portal for an Era of Health and Sustainability

Oct 25, 2023: Faes Farma Reaches a Net Profit of 74 Million Euros in the First Nine Months of 2023

Jul 28, 2023: Faes Farma Achieves a Net Profit of 53 Million Euros in the First Half of the Year

Apr 26, 2023: Faes Farma Increases Its Net Profit by 4% in the First Quarter, Reaching

27.6 Million Euros

Apr 19, 2023: Faes Farma : HANTURA Project

Mar 14, 2023: Development of new diagnostic devices and immunomodulatory drugs based on 25(OH)D and VDR receptor agonists for the treatment of vitamin D deficiency and associated pathologies

Feb 28, 2023: Faes Farma achieves a consolidated profit of

89.5 million euros, 8.6% more than in 2021

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Faes Farma SA, Key Facts

Faes Farma SA, Key Employees

Faes Farma SA, Major Products and Services

Faes Farma SA, History

Faes Farma SA, Subsidiaries

Faes Farma SA, Key Competitors

Faes Farma SA, Ratios based on current share price

Faes Farma SA, Annual Ratios

Faes Farma SA, Annual Ratios (Cont…1)

Faes Farma SA, Annual Ratios (Cont…2)

Faes Farma SA, Interim Ratios

Faes Farma SA, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024

Faes Farma SA, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024

Faes Farma SA, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Faes Farma SA, Performance Chart (2019 – 2023)

Faes Farma SA, Ratio Charts

Faes Farma SA, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024

Faes Farma SA, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports